L. A. Jackson, A. Gurtman, M. van Cleeff, R. W. Frenck, J. Treanor, K. U. Jansen, et al., “Influence of Initial Vaccination with 13-Valent Pneumococcal Conjugate Vaccine or 23-Valent Pneumococcal Polysaccharide Vaccine on Anti-Pneumococcal Responses Following Subsequent Pneumococcal Vaccination in Adults 50 Years and Older,” Vaccine, Vol. 31, No. 35, 2013, pp. 3594-3602. http://dx.doi.org/10.1016/j.vaccine.2013.04.084

has been cited by the following article:

• TITLE: Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Elderly Adults Previously Immunized with a 23-Valent Pneumococcal Polysaccharide Vaccine: An Open-Label Trial

  AUTHORS: Tino F. Schwarz, Karlis Pauksens, Christine Juergens, Deepthi Jayawardene, Daniel A. Scott, William C. Gruber, Beate Schmoele-Thoma

  KEYWORDS: 13-Valent Pneumococcal Conjugate Vaccine; 23-Valent Pneumococcal Polysaccharide Vaccine; Streptococcus pneumoniae; Reactogenicity; Safety

  JOURNAL NAME: World Journal of Vaccines, Vol.3 No.4, September 30, 2013

  ABSTRACT: An open-label, multicenter study was conducted to describe the safety of the 13-valent pneumococcal conjugate vaccine (PCV13) in 1049 individuals aged ≥68 years, who had previously been immunized with the unconjugated 23-valent pneumococcal polysaccharide vaccine (PPSV23). In addition, the safety profile of PCV13 in this study was compared, in a post-hoc descriptive analysis, to that observed in other elderly populations, who had received PCV13 or PPSV23 as part of other completed studies. Local (56.6%) and systemic reactions (58.4%) were very common, but were mainly mild, and of short duration (mean: 1.3 - 4.6 days). There were no related serious adverse events (AEs) within 1 month after PCV13. 123 days after PCV13 and 94 days after a nonstudy influenza vaccine, a case of transient Guillain-Barré syndrome occurred, which the investigator assessed as possibly related to the vaccination. Reactogenicity observed in this study population was generally similar to that of other elderly study populations with PPSV23-preimmunized adults, and with PPSV23-naive adults. Reactogenicity was less common in this study than that observed in PPSV23-preimmunized adults who were revaccinated with PPSV23 rather than a subsequent dose of PCV13. There were no related serious AEs reported after PCV13 and PPSV23 in these comparator studies. Conclusion: PCV13 may be administered safely to older adults previously immunized with PPSV23. (ClinicalTrials. gov Identifier: NCT00500266)